Table 1.
Baseline characteristics
| Overall (n = 205) | REFLECT-in (n = 110) | REFLECT-out (n = 95) | |
|---|---|---|---|
| Age, years | |||
| Mean | 67.7 (SD 10.5) | 68.9 (SD 10.6) | 66.3 (SD 10.2) |
| Median | 69 | 71 | 67 |
| Sex | |||
| Male | 167 (81.5) | 87 (79.1) | 80 (84.2) |
| Female | 38 (18.5) | 23 (20.9) | 15 (15.8) |
| Weight | |||
| <60 kg | 20 (9.7) | 14 (12.7) | 6 (6.4) |
| >60 kg | 177 (86.3) | 91 (82.7) | 86 (90.5) |
| No data available | 8 (4) | 5 (4.6) | 3 (3.1) |
| Vital status at last follow-up | |||
| Dead | 110 (53.7) | 53 (48.2) | 57 (60.0) |
| Alive | 76 (37.1) | 46 (41.8) | 30 (31.6) |
| Lost to follow-up | 19 (9.2) | 11 (10.0) | 8 (8.4) |
| Follow-up time, months | |||
| Mean | 10.7 | 12.2 | 8.4 |
| Median | 8.8 | 9.9 | 6.9 |
| ECOG performance status at baseline | |||
| 0 | 85 (41.5) | 52 (47.3) | 33 (34.7) |
| 1 | 91 (44.4) | 55 (50.0) | 36 (37.9) |
| 2 | 23 (11.2) | 0 | 23 (24.3) |
| >2 | 0 | 0 | 0 |
| No data available | 6 (2.9) | 3 (2.7) | 3 (3.1) |
| BCLC status at baseline | |||
| BCLC A (early) | 6 (2.9) | 4 (3.6) | 2 (2.1) |
| BCLC B (intermediate) | 58 (28.3) | 41 (37.3) | 17 (17.9) |
| BCLC C (advanced) | 141 (68.8) | 65 (59.1) | 76 (80.0) |
| Child-Pugh score at baseline | |||
| Child-Pugh A | 160 (78.4) | 110 (100) | 50 (52.6) |
| Child-Pugh B | 45 (21.6) | 0 | 45 (47.4) |
| Child-Pugh C | 0 | 0 | 0 |
| ALBI grade at baseline | |||
| ALBI 1 | 70 (34.1) | 51 (46.4) | 19 (20.0) |
| ALBI 2 | 116 (56.6) | 55 (50.0) | 61 (64.2) |
| ALBI 3 | 19 (9.3) | 4 (3.6) | 15 (15.8) |
| Etiology | |||
| Alcohol related | 52 (25.3) | 26 (23.6) | 26 (27.4) |
| Hepatitis B | 26 (12.7) | 12 (10.9) | 14 (14.7) |
| Hepatitis C | 32 (15.6) | 18 (16.4) | 14 (14.7) |
| Nonalcoholic steatohepatitis | 42 (20.5) | 23 (20.9) | 19 (20.0) |
| Others | 12 (5.9) | 4 (3.6) | 8 (8.5) |
| Unknown | 41 (20.0) | 27 (24.6) | 14 (14.7) |
| Presence of portal vein thrombosis/extrahepatic spread | |||
| Main portal vein invasion | 47 (22.9) | 0 | 47 (49.5) |
| Extrahepatic spread | 80 (39.0) | 46 (41.8) | 34 (35.8) |
| PVI, EHS, or both | 112 (54.6) | ||
| AFP at baseline | |||
| AFP ≥200 ng/mL | 87 (42.4) | 38 (34.5) | 49 (51.6) |
| AFP ≥400 ng/mL | 75 (36.6) | 31 (28.2) | 44 (46.3) |
| Median AFP, ng/mL | 58.8 | 16.6 | 349 |
| Previous treatment | |||
| Any previous anticancer procedure | 148 (72.2) | 88 (80.0) | 60 (63.2) |
| Resection | 53 (25.8) | 37 (33.6) | 16 (16.8) |
| Transplantation | 4 (1.9) | 4 (3.6) | 0 |
| Radiation | 6 (2.9) | 3 (2.7) | 3 (3.1) |
| Ablation | 46 (22.4) | 29 (26.4) | 17 (17.9) |
| SIRT | 31 (15) | 21 (19.1) | 10 (10.5) |
| TACE | 87 (42.4) | 46 (41.8) | 41 (43.2) |
| No previous treatment | 57 (27.8) | 22 (20) | 35 (36.8) |
| Lenvatinib dose at baseline | |||
| Standard dose at baseline | 89 (43.4) | 52 (47.3) | 37 (38.9) |
| Reduced dose at baseline | 114 (55.6) | 56 (50.9) | 58 (61.1) |
| No data available | 2 (1.0) | 2 (1.8) | 0 |
Baseline characteristics of patients that meet (REFLECT-in) or do not meet the inclusion criteria of the REFLECT trial (REFLECT-out).